STOCK TITAN

Merck names Douglas M. Baker, Jr. independent lead director

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Merck & Co., Inc. said Thomas H. Glocer intends to retire from its Board of Directors in May 2027, at the company’s Annual Meeting of Shareholders. Merck stated that his retirement is not due to any disagreement concerning the company’s operations, policies or practices.

The Board’s independent members appointed Douglas M. Baker, Jr. as independent lead director, effective January 1, 2027, succeeding Glocer in the role. Baker has served on Merck’s Board since 2022 and previously was chairman and chief executive officer of Ecolab Inc.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Board retirement May 2027 At Merck’s Annual Meeting of Shareholders
Independent lead director appointment January 1, 2027 Effective date
Baker’s Merck board service Since 2022 Douglas M. Baker, Jr. has served on the Board since then
independent lead director technical
"appointed ... as independent lead director"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When does Thomas H. Glocer plan to leave the Merck (MRK) board?

Glocer intends to retire at Merck’s Annual Meeting of Shareholders in May 2027. Merck stated that his retirement is not due to any disagreement concerning the company’s operations, policies or practices.

Who will become Merck’s (MRK) independent lead director, and when?

Douglas M. Baker, Jr. will become independent lead director effective January 1, 2027. The Board’s independent members appointed him to succeed Glocer in the role. Baker has served on Merck’s Board since 2022.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0000310158FALSE00003101582026-10-092026-10-090000310158us-gaap:CommonStockMember2026-10-092026-10-090000310158mrk:A3.250NotesDue2032Member2026-10-092026-10-090000310158mrk:A2.500Notesdue2034Member2026-10-092026-10-090000310158mrk:A1.375Notesdue2036Member2026-10-092026-10-090000310158mrk:A3.500NotesDue2037Member2026-10-092026-10-090000310158mrk:A3.700NotesDue2044Member2026-10-092026-10-090000310158mrk:A3.750NotesDue2054Member2026-10-092026-10-09

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported) November 18, 2026 (November 16, 2026)
 
Merck & Co., Inc.
(Exact name of registrant as specified in its charter)
 
New Jersey
1-6571
22-1918501
(State or other jurisdiction of incorporation)(Commission File Number)(I.R.S Employer Identification No.)

126 East Lincoln Avenue
Rahway
New Jersey
07065
(Address of principal executive offices)
(Zip Code)
 (Registrant’s telephone number, including area code) (908) 740-4000
 
Not applicable
(Former name, former address and former fiscal year, if changed since last report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock ($0.50 par value)MRKNew York Stock Exchange
3.250% Notes due 2032MRK/32New York Stock Exchange
2.500% Notes due 2034MRK/34New York Stock Exchange
1.375% Notes due 2036MRK 36ANew York Stock Exchange
3.500% Notes due 2037MRK/37New York Stock Exchange
3.700% Notes due 2044MRK/44New York Stock Exchange
3.750% Notes due 2054MRK/54New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On November 16, 2026, Thomas H. Glocer gave notice to Merck & Co., Inc. (the “Company”) of his intention to retire from the Board of Directors of the Company (the “Board”) as of the Company’s 2027 Annual Meeting of Shareholders. Mr. Glocer’s retirement from the Board is not due to any disagreement with the Company with respect to any matter relating to the Company’s operations, policies or practices.


Item 9.01. Financial Statements and Exhibits.

    (d)    Exhibits

    Exhibit 99.1    Press release issued November 18, 2026

    Exhibit 104    Cover Page Interactive Data File (embedded within the Inline XBRL document)



SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Merck & Co., Inc.
Date: November 18, 2026
By:/s/ Kelly E. W. Grez
Kelly E. W. Grez
Corporate Secretary


Confidential
    - 1 -
image_0.jpg        News Release
____________________________________________________________________________
FOR IMMEDIATE RELEASE

Thomas H. Glocer to Retire from Merck Board of Directors in May 2027;
Douglas M. Baker, Jr. Appointed Independent Lead Director

RAHWAY, N.J., Nov. 18, 2026 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Thomas H. Glocer intends to retire from the Merck Board of Directors at the Company’s Annual Meeting of Shareholders in May 2027. The independent members of the Board have appointed Douglas M. Baker, Jr., as independent lead director, effective Jan. 1, 2027, succeeding Mr. Glocer in the role.

Mr. Baker has served on the Merck Board of Directors since 2022. He has wide-ranging expertise in corporate governance and organizational management, including a deep understanding of global marketing, sales and operations of public companies. Previously, Mr. Baker was chairman and chief executive officer of Ecolab Inc., a provider of water and hygiene services and technologies for the food, hospitality, industrial and energy markets. He is also a trustee of Mayo Clinic.
“Merck has counted on Tom’s expertise and counsel as a trusted voice in our boardroom for many years, and I have relied on him as a valued collaborator. His contributions to our Company have been invaluable, and on behalf of everyone at Merck, I thank him for his dedicated service,” said Rob Davis, chairman and chief executive officer, Merck. “As we look ahead, Doug is a thoughtful, experienced and accomplished leader who will undoubtedly serve the Board well in this expanded role. I look forward to our continued work together as we deliver value to our stakeholders.”

 
About Merck
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world — and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on
X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.


Confidential
    - 2 -

Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA (the “Company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the Company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and the Company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

###


Media Contacts:
Investor Contacts:

Michael Levey
michael.levey@merck.com

John Cummins
john.cummins2@merck.com

Peter Dannenbaum
(732) 594-1579

Steven Graziano
(732) 594-1583


Filing Exhibits & Attachments

5 documents

Keep reading